General Electric Company

Nammi Therapeutics, Inc.

Nanopharmaceuticals LLC

Pfizer Products Inc.

Global Life Sciences Solutions Operations UK Ltd

Bruce Allan Hay

Shaker Ahmed Mousa

Michael Aaron Brodney

Brian Christopher Bales

David Stover

Tahmineh Safaie

Dhruba Bharali

Binil Itty Ipe Kandapallil

Michael Todd Luttrell

Robert Edgar Colborn

Matthew David Butts

Andrew Soliz Torres

Peter John Bonitatibus, Jr

Amit Mohan Kulkarni

Daniel Eugene Meyer

Jack Mathew Webster

Michael Ernest Marino

Thomas Kwok-Fah Foo

Amit Kulkarni

Erik Leeming Kvam

Luca Marinelli

Brian James Grimmond

Ernest William Kovacs

Dominic Michael Graziani

Ozlem O Karakus

Michacl Ernest Marino

Subas Man Sakya

Peter John Bonitatibus Jr

Brian C Bales

Edward Lee Conn

Bruce Allen Lefker

Matthew David Wessel

Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Formulated and/or co-formulated liposome compositions containing toll-like receptor('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof

Formulated and/or co-formulated liposomes comprising IDO prodrugs and methods of making the liposomes are disclosed herein. The IDO prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit IDO-1. The IDO prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof

Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising PD-1 Prodrugs and methods of making the nanocarriers are disclosed herein. The PD-1 Prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit PD-1-L1/L2. The PD-1 Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof

Formulated and/or co-formulated liposome compositions containing toll-like receptor ('TLR') agonist prodrugs useful in the treatment of cancer and methods thereof

Formulated and/or co-formulated liposomes (LNP) and solid-lipid nanoparticles (SLNP) comprising TB Prodrugs and methods of making the LNPs and SLNPs are disclosed herein. The TB prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit ALK5. The TB Prodrugs can be formulated and/or co-formulated into a liposome or solid-lipid nanoparticle to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof

Chemical compounds/compositions, methods of synthesis, and methods of use are provided. The compounds/compositions are directed toward thyrointegrin antagonists directly conjugated to a polymer. The compounds/compositions may further comprise an additional substituent also conjugated to the polymer. The compounds/compositions may demonstrate antiangiogenic effect and efficacy against conditions, particularly cancers.

Polymer conjugated thyrointegrin antagonists

Chemical compounds/compositions, methods of synthesis, and methods of use. The compounds/compositions are directed toward thyrointegrin antagonists conjugated to a polymer. The compounds/compositions further comprise an additional substituent also conjugated to the polymer. The compounds/compositions demonstrate increased uptake across the blood brain barrier along with increased retention therein and retention within tumor. The compounds/compositions may also include improved synthesis scalability, improved purity, improved aqueous solubility, and a solid product or intermediate. The compounds/compositions may demonstrate improved antiangiogenic effect and improved efficacy against conditions, particularly cancers, requiring blood brain barrier permeability, for example, glioblastoma (GBM).

Composition of scalable thyrointegrin antagonists with improved retention in tumors

Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors

A method for purification of a target in a solution includes providing a target in a solution, the solution comprising one or more contaminants, providing a polymer conjugate in the solution, wherein the polymer conjugate is configured to specifically bind the target, incubating the solution at a first temperature to facilitate binding of the polymer conjugate to the target, providing an environmentally-responsive block copolymer in the solution, wherein the environmentally-responsive block copolymer comprises one or more of an ethylene oxide (EO), a propylene oxide (PO), or an EO/PO block copolymer, and heating the solution comprising the environmentally-responsive block copolymer and the polymer conjugate bound to the target at a second temperature to initiate a liquid-liquid phase separation, wherein the liquid-liquid phase separation produces an aqueous phase and a liquid polymer phase, and wherein the liquid polymer phase comprises the polymer conjugate bound to the target.

Method of isolation of polypeptide-aptamer-polymer conjugates

Magnetic material imaging (MMI) system including first and second sets of field-generating coils. Each of the field-generating coils of the first and second sets has an elongated segment that extends along an imaging axis of the medical imaging system. The imaging axis extends through a region-of-interest (ROI) of an object. The elongated segments of the first set of field-generating coils are positioned opposite the elongated segments of the second set of field-generating coils and the ROI is located between the first and second sets of field-generating coils. The MMI system also includes a coil-control module configured to control a flow of current through the first and second sets of field-generating coils to generate a selection field and to generate a drive field. The selection and drive fields combine to form a movable 1D field free region (FFR) that extends through the ROI.

Systems and methods for magnetic material imaging

The present application discloses treating water insoluble nanoparticles, particularly nanoparticles of metals and metal compounds which find utility in diagnostic imaging such as MR and X-ray imaging, with an alpha-hydroxyphosphonic acid conjugate with a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are ethylene oxide based polymers and copolymers and zwitterions and the nanoparticles are composed of transition metal oxides such as superparamagnetic iron oxide and tantalum oxide. Disclosed are nanoparticles which are sufficiently hydrophilic to form stable aqueous colloidal suspensions. Also disclosed is diagnostic imaging such as MR and X-ray using the modified hydrophilic nanoparticles as contrast agents.

Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents

The present application discloses nanoparticles, particularly nanoparticles of superparamagnetic iron oxide, which find utility in iron therapy and diagnostic imaging such as magnetic resonance (MR). The disclosed nanoparticles have been treated with an &#x3b1;-hydroxyphosphonic acid conjugate containing polyethylene glycol as a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are polyethylene oxide-based polymers and have a molecular weight greater than 5,000 dalton and less than or equal to about 30,000 daltons. Surprisingly, these nanoparticles have a more rapid and complete processing in liver of retained nanoparticles when compared to similar nanoparticles in which the PEG-based hydrophilic moiety has a molecular weight less than 5,000.

Superparamagnetic nanoparticles with PEG substituted &#x3b1;-hydroxy phosphonate shells

Growing community of inventors

Niskayuna, NY, United States of America

Bruce Allan Hay